摘要
The introduction of erythropoiesis-stimulating agents (ESAs) markedly improved the lives of many anaemic patients with chronic kidney disease (CKD). In Taiwan, the strategy of management of anaemia in patients with CKD was different from many other parts of the world. In 1996, the National Health Insurance Administration of Taiwan applied a more restrictive reimbursement criteria for ESA use in patients with CKD. ESA is to be initiated when non-dialysis CKD patients have a serum creatinine >6 mg/dL and a hematocrit
原文 | 英語 |
---|---|
頁(從 - 到) | 735-739 |
頁數 | 5 |
期刊 | Nephrology |
卷 | 19 |
發行號 | 12 |
DOIs | |
出版狀態 | 已發佈 - 12月 1 2014 |
對外發佈 | 是 |
ASJC Scopus subject areas
- 腎臟病學
- 醫藥 (全部)